D-0006-2026 Class II Ongoing

Recalled by ACCORD HEALTHCARE, INC. — Raleigh, NC

FDA drug recall D-0006-2026 was initiated by ACCORD HEALTHCARE, INC. on Sep 16, 2025 and is designated Class II. Reason for recall: Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range. The recall status is ongoing. Affected quantity: 54,432 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 15, 2025
Initiation Date
Sep 16, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
54,432 bottles

Product description

Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15.

Reason for recall

Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.

Distribution pattern

Nationwide in the US

Code information

Lot # D2300045, Exp 12/31/2025.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0006-2026
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0006-2026. Report a data issue: hello@regdatalab.com.